Roy Lester Freeman - 03 Jan 2025 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Director
Signature
/s/ Milton H. Werner, attorney-in-fact
Issuer symbol
IKT
Transactions as of
03 Jan 2025
Net transactions value
$0
Form type
4
Filing time
07 Jan 2025, 18:39:26 UTC
Previous filing
18 Jul 2024
Next filing
22 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (Right to Buy) Award $0 +344,452 $0.000000 344,452 03 Jan 2025 Common Stock 344,452 $1.26 Direct F1
transaction IKT Stock Option (Right to Buy) Award $0 +172,191 $0.000000 172,191 03 Jan 2025 Common Stock 172,191 $1.45 Direct F2
transaction IKT Stock Option (Right to Buy) Award $0 +316,647 $0.000000 316,647 03 Jan 2025 Common Stock 316,647 $1.58 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vested and became exercisable on October 9, 2024.
F2 The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series A-1 Warrants in an amount proportional to the actual number of Series A-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.
F3 The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series B-1 Warrants in an amount proportional to the actual number of Series B-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.